Invest In

Revolutionizing the Way to Treat Neurodegenerative Disease.

Almost all of us know–or will know–someone who suffers from Alzheimer’s, Parkinson’s, Multiple Sclerosis, PTSD, or another debilitating brain disease. It’s difficult to see people we love struggle so much–and it’s even more difficult to find treatment options that are simple, non-invasive, and effective. . . until now.

The Problem

The Cost of Doing Nothing

The cumulative physical, emotional, and financial effect of Central Nervous System (CNS) disorders on patients and their caretakers is utterly devastating. The latest data projects that by 2025, the number of people suffering from Alzheimer’s alone is set to increase by 22%–putting enormous strain on our healthcare system, not to mention the families who care for their aging loved ones.

What does an investment in Kurve Therapeutics mean?

0 million
Americans currently in
the cognitive aging market
$ 0 billion
In productivity loss among friends and family providing unpaid care for Alzheimer’s patients in 2020
$ 0 billion
The total national cost of caring for Alzheimer’s and dementia patients annually in the U.S.

The solution

The ViaNase™ Difference

Researchers and scientists have spent the last 25 years trying and failing to develop effective treatments for brain diseases. The majority of the traditional treatments methods available can’t bypass the blood brain barrier, leaving the majority of the medication behind in the nasal cavity, sinuses, or GI tract. Other methods also can produce a number of undesirable side effects.

ViaNase™ Intelligent Delivery holds the key to overcoming this frustrating obstacle. This modified approach to treating Central Nervous System disorders uses Kurve Therapeutics’ patented Controlled Particle Dispersion technology to deliver medication precisely where it is needed, providing relief and a sense of wellbeing for patients battling brain disease.

01

Reduction in systemic side effects

02

Enhances the opportunity for bioavailability

03

Non-invasive / painless

04

Odorless / tasteless

05

User-friendly

06

Increased patient compliance

07

Convenient / portable

08

Lightweight / pocket-sized

09

Battery powered

10

Fast and easy to administer

The Proof

Thoroughly Vetted

Kurve Therapeutics’ revolutionary treatment system is featured in 18 peer-reviewed publications by
leading institutions such as:

clinical trials

Rigorously Tested

We hold to the highest levels of transparency and integrity when it comes to sharing the results of our ongoing clinical trial phase. So far, we’ve met our endpoints in 3 separate clinical trials (Phase 2b) and are cleared to begin Phase 3. Here’s the latest trials we’ve participated in where our next-generation technology was the device of choice:

*Clinical trial reports available upon request

The Opportunity

Here’s where you come in.

In 2022, Kurve Therapeutics filed a Regulation A offering with the SEC. This means we can officially offer investment opportunities for the general public to partner with us as we continue to conduct clinical studies. If these studies prove successful–and all indications are favorable that they will–we will officially move into the next stages of product development and launch.

The offering

Shape The Future With Us

It’s simple. With your partnership, we have the unprecedented opportunity to change the lives of millions of people battling CNS disorders and give their families the best gift of all: peace of mind. There’s never been a better time to get in on the ground floor of this unprecedented opportunity.

$50M

Total Filing Raise

$580

Minimum Investment

$5.80

Price Per Share

Sign up to Invest Now

Video Introduction

Kurve is at the forefront of a new era of central nervous system disorder treatments.

Play Video

About Kurve Therapeutics

Our Mission and Vision

To put it simply: we do this because we can and because we have to.

Our mission is to help as many people as we possibly can in their fight with neurodegenerative disorders. Our hope is that these complex debilitating disorders may have a solution when paired with the right medication and the right technology. Our goal is to enhance the quality of life for patients and provide a solution where their past treatments have failed them–to give people a renewed sense of hope for the future.

The Team Behind Kurve

Meet Our Medtech Innovators

Marc Giroux

CHAIRMAN & CHIEF EXECUTIVE OFFICER

Marc’s lifelong battle with chronic sinusitis and allergies pushed him to develop a new intranasal therapy solution that would actually work. His background in high-end manufacturing and product development gave him the tools he needed to invent a better option for intranasally delivered treatments. After developing Kurve’s patented delivery system, he realized that he could utilize this technology in ways beyond sinus and allergy treatments.

Glenn Cornett, M.D., Ph.D.

CHIEF SCIENCE OFFICER

Dr. Glenn Cornett is a biotech entrepreneur and advisor. He holds an M.D. with Distinction in Research from the University of Michigan and a Ph.D. in neuroscience from UCLA. He has spent the past decade developing drugs for psychiatric and neurological indications.

Tom S. McDowell

CHIEF OPERATING OFFICER

Tom is a skilled and accomplished COO with forty years of experience in accounting, financial reporting, investment banking, and mergers & acquisitions for established and start-up companies. He has consulted with over 25 startups and early-stage companies in the software, telecommunications, financial management, retail, manufacturing, consulting and distribution industries.

Download our
FREE Investor Deck

See how Kurve is Revolutionizing the Way to Treat Neurodegenerative Disease.